{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:47:39Z","timestamp":1782370059926,"version":"3.54.5"},"reference-count":81,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2002,5,1]],"date-time":"2002-05-01T00:00:00Z","timestamp":1020211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Pharmaceutical Association (1996)"],"published-print":{"date-parts":[[2002,5]]},"DOI":"10.1331\/108658002763316888","type":"journal-article","created":{"date-parts":[[2003,6,17]],"date-time":"2003-06-17T16:53:18Z","timestamp":1055868798000},"page":"449-459","source":"Crossref","is-referenced-by-count":26,"title":["Intravenous Immunoglobulins: Clinical Experience and Viral Safety"],"prefix":"10.1016","volume":"42","author":[{"given":"Mark","family":"Ballow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1331\/108658002763316888_bb0010","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","article-title":"Agammaglobulinemia.","volume":"9","author":"Bruton","year":"1952","journal-title":"Pediatrics."},{"key":"10.1331\/108658002763316888_bb0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2500\/108854194778816445","article-title":"Use of intravenous immunoglobulin (IVIG) therapy in adults.","volume":"15","author":"Herrod","year":"1994","journal-title":"Allergy Proc."},{"key":"10.1331\/108658002763316888_bb0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJM197208172870709","article-title":"Giardiasis with malabsorption in X-linked agammaglobulinemia.","volume":"287","author":"Ochs","year":"1972","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316888_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-3476(80)80131-4","article-title":"Chronic rotavirus infection in immunodeficiency.","volume":"97","author":"Saulsbury","year":"1980","journal-title":"J Pediatr."},{"key":"10.1331\/108658002763316888_bb0030","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/0002-9343(86)90812-0","article-title":"Increased susceptibility to mycoplasma infection in patients with hypogammaglobulinemia.","volume":"80","author":"Roifman","year":"1986","journal-title":"Am J Med."},{"key":"10.1331\/108658002763316888_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/08820139109050786","article-title":"Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy.","volume":"20","author":"Chapel","year":"1991","journal-title":"Immunol Invest."},{"key":"10.1331\/108658002763316888_bb0040","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2249.1992.tb06965.x","article-title":"Predictors of infection in chronic lymphocytic leukaemia (CLL).","volume":"89","author":"Griffiths","year":"1992","journal-title":"Clin Exp Immunol."},{"issue":"suppl 1","key":"10.1331\/108658002763316888_bb0045","first-page":"21","article-title":"The use of intravenous immune globulin in multiple myeloma.","volume":"97","author":"Chapel","year":"1994","journal-title":"Clin Exp Immunol."},{"key":"10.1331\/108658002763316888_bb0050","first-page":"121","article-title":"Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study.","volume":"81","author":"Molica","year":"1996","journal-title":"Haematologica."},{"key":"10.1331\/108658002763316888_bb0055","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma.","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J Clin Pathol."},{"key":"10.1331\/108658002763316888_bb0060","first-page":"543","article-title":"Intravenous immunoglobulin in symptomatic and asymptomatic children with perinatal HIV infection.","volume":"89","author":"Olopoenia","year":"1997","journal-title":"J Natl Med Assoc."},{"key":"10.1331\/108658002763316888_bb0065","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/ajhp\/52.8.803","article-title":"Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients.","volume":"52","author":"Crow","year":"1995","journal-title":"Am J Health Syst Pharm."},{"key":"10.1331\/108658002763316888_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0002-9343(87)90549-3","article-title":"Immunoglobulin therapy in bone marrow transplantation.","volume":"83","author":"Sullivan","year":"1987","journal-title":"Am J Med."},{"key":"10.1331\/108658002763316888_bb0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJM199009133231103","article-title":"Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation.","volume":"323","author":"Sullivan","year":"1990","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316888_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1056\/NEJM199207233270404","article-title":"The Intravenous Immunoglobulin Collaborative Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection","volume":"327","year":"1992","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316888_bb0085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01711930","article-title":"Effect of adjuvant immunoglobulin therapy on infections in patients in a surgical intensive care unit. Results of a randomized controlled study [in German].","volume":"64","author":"Just","year":"1986","journal-title":"Klin Wochenschr."},{"key":"10.1331\/108658002763316888_bb0090","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/BF00273538","article-title":"Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study.","volume":"11","author":"Glinz","year":"1985","journal-title":"Intensive Care Med."},{"key":"10.1331\/108658002763316888_bb0095","first-page":"4","article-title":"Immunotherapy of surgical sepsis [in Russian].","volume":"1","author":"Malinovskii","year":"1997","journal-title":"Khirurgiia (Mosk)."},{"key":"10.1331\/108658002763316888_bb0100","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology.","volume":"88","author":"George","year":"1996","journal-title":"Blood."},{"key":"10.1331\/108658002763316888_bb0105","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood.V72.1.121.121","article-title":"Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin [see Comments].","volume":"72","author":"Bussel","year":"1988","journal-title":"Blood."},{"key":"10.1331\/108658002763316888_bb0110","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3476(83)80608-8","article-title":"Intravenous use of gammaglobulin in the treatment of chronic immune thrombocytopenic purpura as a means to defer splenectomy.","volume":"103","author":"Bussel","year":"1983","journal-title":"J Pediatr."},{"key":"10.1331\/108658002763316888_bb0115","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1096-8652(199810)59:2<127::AID-AJH5>3.0.CO;2-#","article-title":"Usefulness of a low-dose intravenous immunoglobulin regimen for the treatment of thrombocytopenia associated with AIDS.","volume":"59","author":"Majluf-Cruz","year":"1998","journal-title":"Am J Hematol."},{"key":"10.1331\/108658002763316888_bb0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V82.1.29.bloodjournal82129","article-title":"Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia.","volume":"82","author":"Oksenhendler","year":"1993","journal-title":"Blood."},{"key":"10.1331\/108658002763316888_bb0125","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1442-200X.1991.tb02612.x","article-title":"Intravenous gamma-globulin treatment in Kawasaki disease.","volume":"33","author":"Harada","year":"1991","journal-title":"Acta Paediatr Jpn."},{"key":"10.1331\/108658002763316888_bb0130","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1542\/peds.96.6.1057","article-title":"The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.","volume":"96","author":"Durongpisitkul","year":"1995","journal-title":"Pediatrics."},{"key":"10.1331\/108658002763316888_bb0135","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7326\/0003-4819-126-9-199705010-00008","article-title":"Intravenous immune globulin therapy for neurologic diseases.","volume":"126","author":"Dalakas","year":"1997","journal-title":"Ann Intern Med."},{"key":"10.1331\/108658002763316888_bb0140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group.","volume":"326","author":"der Meche","year":"1992","journal-title":"N Engl J Med."},{"issue":"9047","key":"10.1331\/108658002763316888_bb0145","first-page":"225","article-title":"Plasma Exchange\/Sandoglobulin Guillain-Barre Syndrome Trial Group.","volume":"349","author":"Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barre-syndrome.","year":"1997","journal-title":"Lancet."},{"key":"10.1331\/108658002763316888_bb0150","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol."},{"issue":"6 suppl 5","key":"10.1331\/108658002763316888_bb0155","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1212\/WNL.51.6_Suppl_5.S16","article-title":"Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin.","volume":"51","author":"Hahn","year":"1998","journal-title":"Neurology."},{"key":"10.1331\/108658002763316888_bb0160","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1212\/WNL.44.3_Part_1.429","article-title":"Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study.","volume":"44","author":"Azulay","year":"1994","journal-title":"Neurology."},{"key":"10.1331\/108658002763316888_bb0165","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","article-title":"A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.","volume":"329","author":"Dalakas","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316888_bb0170","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-101-4-435","article-title":"Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease.","volume":"101","author":"Cunningham-Rundles","year":"1984","journal-title":"Ann Intern Med."},{"key":"10.1331\/108658002763316888_bb0175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9343(85)90006-3","article-title":"Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease.","volume":"79","author":"Roifman","year":"1985","journal-title":"Am J Med."},{"issue":"8541","key":"10.1331\/108658002763316888_bb0180","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinemia and chronic lung disease.","volume":"1","author":"Roifman","year":"1987","journal-title":"Lancet."},{"key":"10.1331\/108658002763316888_bb0185","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0090-1229(87)90123-1","article-title":"Results of a prospective controlled two-dose crossover study with intravenous immunoglobulin and comparison (retrospective) with plasma treatment.","volume":"43","author":"Bernatowska","year":"1987","journal-title":"Clin Immunol Immunopathol."},{"key":"10.1331\/108658002763316888_bb0190","first-page":"335","article-title":"High-vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia.","volume":"146","author":"Liese","year":"1992","journal-title":"Am J Dis Child."},{"key":"10.1331\/108658002763316888_bb0195","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0002-9343(84)90324-3","article-title":"Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases.","volume":"76","author":"Ochs","year":"1984","journal-title":"Am J Med."},{"key":"10.1331\/108658002763316888_bb0200","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/00006454-199707000-00012","article-title":"Human intravenous immunoglobulin in primary and secondary antibody deficiencies.","volume":"16","author":"Stiehm","year":"1997","journal-title":"Pediatr Infect Dis J."},{"key":"10.1331\/108658002763316888_bb0205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1027380210989","article-title":"Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases.","volume":"17","author":"Schiff","year":"1997","journal-title":"J Clin Immunol."},{"key":"10.1331\/108658002763316888_bb0210","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1046\/j.1423-0410.1998.7420074.x","article-title":"IVIG adverse reactions: potential role of cytokines and vasoactive substances.","volume":"74","author":"Bagdasarian","year":"1998","journal-title":"Vox Sang."},{"key":"10.1331\/108658002763316888_bb0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1542\/pir.16-11-403","article-title":"Therapeutic uses of intravenous immunoglobulin (IVIG) in children.","volume":"16","author":"Ramesh","year":"1995","journal-title":"Pediatr Rev."},{"key":"10.1331\/108658002763316888_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0887-7963(05)80026-4","article-title":"IgA anaphylactic transfusion reactions.","volume":"9","author":"Sandier","year":"1995","journal-title":"Transfus Med Rev."},{"key":"10.1331\/108658002763316888_bb0225","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF01541089","article-title":"Long-term follow-up of anti-IgA antibodies in healthy IgA-deficient adults.","volume":"15","author":"Koskinen","year":"1995","journal-title":"J Clin Immunol."},{"key":"10.1331\/108658002763316888_bb0230","first-page":"83","article-title":"Pulmonary and renal toxicity of intravenous immunoglobulin.","volume":"36","author":"Rault","year":"1991","journal-title":"Clin Nephrol."},{"key":"10.1331\/108658002763316888_bb0235","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/j.1875-9114.1995.tb02894.x","article-title":"Acute renal failure after administration of intravenous immunoglobulin: review of literature and case report.","volume":"15","author":"Winward","year":"1995","journal-title":"Pharmacotherapy"},{"key":"10.1331\/108658002763316888_bb0240","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/0272-6386(95)90003-9","article-title":"Acute renal failure with immunoglobulin therapy.","volume":"25","author":"Cantu","year":"1995","journal-title":"Am J Kidney Dis."},{"key":"10.1331\/108658002763316888_bb0245","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1159\/000169055","article-title":"Acute renal failure following immunoglobulin therapy.","volume":"16","author":"Ahsan","year":"1996","journal-title":"Am J Nephrol."},{"key":"10.1331\/108658002763316888_bb0250","first-page":"159","volume":"48","author":"Availability of immune globulin intravenous for treatment of immune deficient patients\u2014United States, 1997-1998","year":"1999","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1331\/108658002763316888_bb0255","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1001\/jama.1995.03520470073035","article-title":"Recommendations for off-label use of intravenously administered immunoglobulin preparations.","volume":"273","author":"Ratko","year":"1995","journal-title":"JAMA."},{"key":"10.1331\/108658002763316888_bb0260","series-title":"Data on file","year":"1997"},{"key":"10.1331\/108658002763316888_bb0265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1537-2995.1986.26486262755.x","article-title":"Lack of seroconversion to human T-cell lymphotropic virus, type III, after intravenous immune globulin.","volume":"26","author":"Bussell","year":"1986","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0270","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1423-0410.1991.tb00953.x","article-title":"Safety of intravenous immunoglobulin preparations: a prospective multicenter study to exclude the risk of non-A, non-B hepatitis.","volume":"61","author":"Imbach","year":"1991","journal-title":"Vox Sang."},{"key":"10.1331\/108658002763316888_bb0275","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1423-0410.1991.tb00876.x","article-title":"Prospective study on the hepatitis safety of intravenous immunoglobulin, pH 4.25.","volume":"60","author":"Rousell","year":"1991","journal-title":"Vox Sang."},{"issue":"suppl 15","key":"10.1331\/108658002763316888_bb0280","first-page":"S115","article-title":"Clinical experience with Octagam, a solvent detergent (SD) virus inactivated intravenous gammaglobulin.","volume":"14","author":"Brenner","year":"1996","journal-title":"Clin Exp Rheumatol."},{"issue":"suppl 1","key":"10.1331\/108658002763316888_bb0285","first-page":"79","article-title":"Side-effects of intravenous immune globulins.","volume":"97","author":"Duhem","year":"1994","journal-title":"Clin Exp Immunol."},{"key":"10.1331\/108658002763316888_bb0290","first-page":"505","article-title":"Outbreak of hepatitis C associated with intravenous immunoglobulin administration\u2014United States, October 1993-June 1994","volume":"43","year":"1994","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.1331\/108658002763316888_bb0295","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/jama.1996.03540190035026","article-title":"Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study.","volume":"276","author":"Bresee","year":"1996","journal-title":"JAMA."},{"key":"10.1331\/108658002763316888_bb0300","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1046\/j.1537-2995.1998.38498257368.x","article-title":"The \u201csafe\u201d blood donor and the national blood supply: is there a new interface?","volume":"38","author":"Davey","year":"1998","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0305","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1537-2995.1998.38498257373.x","article-title":"Demographic characteristics, unreported risk behaviors, and the prevalence and incidence of viral infections: a comparison of apheresis and whole-blood donors.","volume":"38","author":"Glynn","year":"1998","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0310","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004010-199301830-00008","article-title":"Recruitment and retention of blood donors: a strategic linkage approach.","volume":"18","author":"Ibrahim","year":"1993","journal-title":"Health Care Manage Rev."},{"key":"10.1331\/108658002763316888_bb0315","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1046\/j.1537-2995.1990.30590296381.x","article-title":"Why do they give the gift of life? A review of research on blood donors since 1977.","volume":"30","author":"Piliavin","year":"1990","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0320","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJM198910053211405","article-title":"Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative.","volume":"321","author":"Cumming","year":"1989","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316888_bb0325","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1046\/j.1537-2995.1998.38498257374.x","article-title":"Retention of \u201csafe\u201d blood donors.","volume":"38","author":"Thomson","year":"1998","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0330","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199606273342601","article-title":"The risk of transfusion-transmitted viral infections.","volume":"334","author":"Schreiber","year":"1996","journal-title":"N Engl J Med."},{"key":"10.1331\/108658002763316888_bb0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1046\/j.1537-2995.1995.35295125745.x","article-title":"Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors.","volume":"35","author":"Busch","year":"1995","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0340","first-page":"139","article-title":"Validation of a PCR assay system to screen plasma for HBV, HCV, and HIV-1.","volume":"25","author":"Weimer","year":"1998","journal-title":"Infusionsther Transfusionsmed."},{"key":"10.1331\/108658002763316888_bb0345","series-title":"Intramuscular Immunoglobulins: Nucleic Acid Amplification Tests for HCV RNA Detection.","year":"1995"},{"key":"10.1331\/108658002763316888_bb0350","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc."},{"key":"10.1331\/108658002763316888_bb0355","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1423-0410.1962.tb03274.x","article-title":"Large scale production of human plasma fractions.","volume":"7","author":"Kistler","year":"1962","journal-title":"Vox Sang."},{"issue":"suppl 15","key":"10.1331\/108658002763316888_bb0360","first-page":"S47","article-title":"Virus validation studies of immunoglobulin preparations.","volume":"14","author":"Biesert","year":"1996","journal-title":"Clin Exp Rheumatol."},{"key":"10.1331\/108658002763316888_bb0365","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1046\/j.1537-2995.1992.32993110753.x","article-title":"Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma.","volume":"32","author":"Yei","year":"1992","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0370","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1423-0410.1994.tb01246.x","article-title":"Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin.","volume":"67","author":"Uemura","year":"1994","journal-title":"Vox Sang."},{"key":"10.1331\/108658002763316888_bb0375","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1537-2995.1999.39399219280.x","article-title":"Virus reduction in the preparation of intravenous immune globulin: in vitro experiments.","volume":"39","author":"Chandra","year":"1999","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0380","series-title":"Gammagard S\/D [package insert]","year":"1995"},{"key":"10.1331\/108658002763316888_bb0385","first-page":"82","article-title":"Inactivation of AIDS-causing retroviruses by the manufacturing procedures for human plasma proteins.","author":"Hilfenhaus","year":"1988","journal-title":"Behring Inst Mitt."},{"key":"10.1331\/108658002763316888_bb0390","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1537-2995.1986.26286152919.x","article-title":"Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma.","volume":"26","author":"Wells","year":"1986","journal-title":"Transfusion (Paris)."},{"key":"10.1331\/108658002763316888_bb0395","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000205727","article-title":"Safety of intravenous immunoglobulin for treatment of auto-immune thrombocytopenia.","volume":"79","author":"Gutteridge","year":"1988","journal-title":"Acta Haematol."},{"issue":"8760","key":"10.1331\/108658002763316888_bb0400","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0140-6736(91)90191-Q","article-title":"Long-term safety and tolerability of intravenous immunoglobulin.","volume":"338","author":"Hany","year":"1991","journal-title":"Lancet."},{"key":"10.1331\/108658002763316888_bb0405","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/biol.1994.1003","article-title":"Inactivation of hepatitis C virus in low pH intravenous immunoglobulin.","volume":"22","author":"Louie","year":"1994","journal-title":"Biologicals."},{"key":"10.1331\/108658002763316888_bb0410","series-title":"Seven Paths to Plasma Safety.","year":"1999"}],"container-title":["Journal of the American Pharmaceutical Association (1996)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215302631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1086580215302631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:25:16Z","timestamp":1704846316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1086580215302631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,5]]},"references-count":81,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,5]]}},"alternative-id":["S1086580215302631"],"URL":"https:\/\/doi.org\/10.1331\/108658002763316888","relation":{},"ISSN":["1086-5802"],"issn-type":[{"value":"1086-5802","type":"print"}],"subject":[],"published":{"date-parts":[[2002,5]]}}}